<html>
<head>PUBMED IDs for Apo-2L</head>
<body bgcolor='#C5F0F2'><h1>Apo-2L</h1><a href='https://pubmed.ncbi.nlm.nih.gov/9434163/'>Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.</a> January 20  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/10229846/'>TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege.</a> May 7  1999<br><a href='https://pubmed.ncbi.nlm.nih.gov/10479402/'>Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity.</a> September 10  1999<br><a href='https://pubmed.ncbi.nlm.nih.gov/10914028/'>Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins.</a> July 29  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/10914013/'>Monitoring activity of caspases and their regulators in yeast Saccharomyces cerevisiae.</a> July 29  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/11461904/'>Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.</a> July 20  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/11774036/'>TRAIL/Apo-2L: mechanisms and clinical applications in cancer.</a> January 5  2002<br><a href='https://pubmed.ncbi.nlm.nih.gov/11781716/'>Three polymorphisms in the 3' UTR of the TRAIL (TNF-related apoptosis-inducing ligand) gene.</a> January 10  2002<br><a href='https://pubmed.ncbi.nlm.nih.gov/12118245/'>Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.</a> July 16  2002<br><a href='https://pubmed.ncbi.nlm.nih.gov/12615723/'>Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.</a> March 5  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/14682494/'>TRAIL: a potential agent for cancer therapy.</a> December 20  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/15110189/'>TRAIL and malignant glioma.</a> April 28  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/15258905/'>Differential control of apoptosis by DJ-1 in prostate benign and cancer cells.</a> July 20  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/15611657/'>Cell Death Inhibiting RNA (CDIR) modulates IFN-gamma-stimulated sensitization to Fas/CD95/Apo-1 and TRAIL/Apo-2L-induced apoptosis.</a> December 22  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/16037389/'>Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.</a> July 23  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/16456549/'>Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.</a> February 4  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/16574768/'>On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils.</a> April 1  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/17620439/'>TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.</a> July 11  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/20605676/'>Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L.</a> October 16  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21520073/'>P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells.</a> January 31  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22322922/'>Gene expression profiling in MOLT-4 cells during gamma-radiation-induced apoptosis.</a> July 10  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24618889/'>Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.</a> May 30  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25173558/'>Bleomycin induced sensitivity to TRAIL/Apo-2L-mediated apoptosis in human seminomatous testicular cancer cells is correlated with upregulation of death receptors.</a> August 13  2014<br></body></html>
